Komoot Unveils Modern Design as Part of Ambitious Product Roadmap
15.9.2025 09:00:00 CEST | Business Wire | Press Release
Komoot, the leading outdoor app, is rolling out a fresh new design: The experience is currently live for Web users worldwide, with Mobile slated for release by the end of September.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915468295/en/
The updated design—the first in a series of major initiatives outlined within komoot’s ambitious new roadmap—introduces a refreshed look and includes significant improvements to the user journey to deliver a more intuitive and enjoyable experience overall. At the same time, komoot’s core navigation and workflows remain the same: The result is a modern, intuitive design that still feels familiar to returning users.
The most notable changes include:
- A contemporary design. The new look introduces several refreshed design elements—such as color palette, fonts, icons, and illustrations—to elevate and modernize the overall komoot brand and user experience.
- A clearer and more intuitive structure. The team introduced improved spacing, visual contrast, content organization, and navigation to streamline information and make useful features more discoverable across Web and Mobile.
- A stronger emphasis on photos for more reliable route previewing. The new design gives priority to photo content, which users frequently rely on to choose or build their route on komoot. Now, users can better leverage over 87 million images to guide their decisions.
“Our goal was to strike a balance between the old and the new,” explains Tom Eldred, Product Manager at komoot. “We kept the elements people already love and only reworked the parts we knew could be made simpler and more intuitive. In the end, it’s the same komoot our community relies on, just with a fresh perspective.”
Built with the community
The new komoot design was built hand-in-hand with the komoot community. The team collected and implemented customer feedback via 110 in-person interviews and over 3,000 online surveys. The initial community response has been favorable: Over 80% of users reported that they preferred the new design, and another 15% said they liked it just as much as the previous version.
First in a series of upcoming product improvements
Since joining the Bending Spoons suite of digital products, komoot has accelerated the rate at which it releases new features and improvements—in the past five months, the team has released over 50 changes for Web, Mobile, and connected devices.
Most recently, the team published a bold roadmap highlighting its key priorities for the coming months. The majority of upcoming changes focus on route discovery and planning, with a sweeping update to the Web Route Planner and the introduction of route descriptions, advanced route filters, preferences, custom saved places, and more.
When previewing the new Web Planner during customer research, cyclist and lifestyle influencer Tegan Phillips commented, “One of my favourite pre-adventure activities is route-planning, which I’ve always loved doing with komoot. With these new changes, that planning process is going to be even simpler and more beautiful—I’m super excited!”
Beyond these features, komoot users can expect improvements to their on-route experience with a new offline mode on Apple Watch and live navigation updates on Mobile. Finally, in 2025, komoot will leverage rich insights from its large user base to create community Heatmaps and streamlined Highlights, both of which draw upon users’ real-life experiences to help others find their next adventure.
With these initiatives, the goal is to improve the everyday user experience and make the platform more intuitive and enjoyable. The full list of previous improvements and details on upcoming features can be viewed here: https://www.komoot.com/product-updates.
About komoot
Komoot is a thriving digital platform for adventurers and outdoor enthusiasts around the world. It’s driven by a simple goal: to help people explore more of the outdoors wherever and however they want. Komoot’s mobile apps and platform provide advanced route planning and navigation tools. At the same time, a content-rich feed of unique stories and adventures inspires its community of over 50 million users to explore and share their outdoor experiences and recommendations. For more information, visit komoot.com.
About Bending Spoons
Bending Spoons has served a billion people across the globe through its suite of digital technology businesses, including Brightcove, Evernote, komoot, Meetup, Remini, StreamYard, and WeTransfer. Its products are currently used by around 300 million people each month.
For more information, visit bendingspoons.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250915468295/en/
Contacts
Media contact
Pauline Stahl
pauline@get-press.de
Media contact
Christy Keenan
ck@bendingspoons.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom